Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-CAR-Super IL2
- Development stage
- Preclinical
- Lead developer
- Synthekine
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral, Intravenous, Intra-arterial, Intratumoral
01
Overview
**GPC3-CAR-Super IL2** is an experimental, GPC3-directed CAR construct designed for transient **in vivo engineering of macrophages** using lipid nanoparticle-delivered mRNA. The construct combines a glypican-3-targeting chimeric antigen receptor with a Super IL-2 component intended to enhance antitumor immune activation, including CD8-positive T-cell proliferation. It was reported as one component of an LNP-mRNA quadrivalent CAR-macrophage approach administered together with FAP-CAR-ΔTGFβRII in preclinical solid-tumor studies. In an orthotopic mouse hepatocellular carcinoma model, the combined system promoted tumor immune activation, CD8-positive T-cell infiltration and expansion, antigen spreading, immune memory, and complete tumor regression without significant reported toxicity. GPC3-CAR-Super IL2 has not been identified as an independently administered clinical drug product.
- Other names
- GPC3 CAR-Super IL2GPC-3 CAR-Super IL2GPC 3 CAR-Super IL2GPC3-CAR-Super IL-2GPC-3-CAR-Super IL-2GPC 3-CAR-Super IL-2
02
Targets
orthoIL-2Rβ (Engineered orthogonal IL-2 receptor beta)GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-CAR-Super IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-CAR-Super IL2.